Why the study?
Is a plan to use androgen deprivation therapy associated with higher baseline cardiovascular risk in men with prostate cancer?
Is a plan to use androgen deprivation therapy associated with higher baseline cardiovascular risk in men with prostate cancer?
The apparent association between planned androgen deprivation therapy and cardiovascular risk in prostate cancer patients is driven by confounding baseline risk factors rather than the therapy plan itself.
High cardiovascular risk warrants routine assessment in prostate cancer patients at diagnosis; cross-sectional data leave causal effects of androgen deprivation therapy open to confounding.
Two-thirds of men with prostate cancer are at high cardiovascular risk. There is a positive association between a plan to use androgen deprivation therapy and baseline cardiovascular risk factors. However, this association is explained by confounding factors.
No takes yet. Share an insight, caveat, or question.
Leong et al. (2020) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: